News Release
2020.01.24
Joint Research with View to Developing Regenerative Medicine Product for Type 1 Diabetes by Producing Pancreatic Beta Cells Through Direct Reprogramming of Bone Marrow-Derived Mesenchymal Stem Cells
Info
2019.12.16
Message from Representative Director and President, Keita Mori, regarding disclosures made on December 13, 2019
News Release
2019.12.16
Q&A Regarding Announcements on December 13, 2019 Concerning “Consolidated Financial Results for the Nine Months Ended October 31, 2019” and “Decision to Terminate a Joint Development and License Agreement for Regenerative Cell Medicine SB623 for Chronic Stroke in North America,”
News Release
2019.12.13
SanBio and Sumitomo Dainippon Pharma Announce a Termination of a Joint Development and License Agreement for Regenerative Cell Medicine SB623 for Chronic Stroke in North America
News Release
2019.09.20
Agreement on Joint Research into SB623 for Indication of Retinal Disease
News Release
2019.09.19
SanBio Granted Regenerative Medicine Advanced Therapy Designation from the U.S. FDA for SB623 for the Treatment of Chronic Neurological Motor Deficits Secondary to Traumatic Brain Injury
News Release
2019.09.13
SanBio announced the results of the Phase 2 STEMTRA trial of SB623 as a treatment for chronic motor deficit from traumatic brain injury, at 2019 World Federation of Neurosurgical Societies Special World Congress
News Release
2019.08.30
SanBio announced the results of the Phase 2 STEMTRA trial of SB623 as a treatment for chronic motor deficit from traumatic brain injury was presented at the Military Health System Research Symposium 2019
News Release
2019.05.15
Bijan Nejadnik, M.D., appointed as Chief Medical Officer of SanBio
News Release
2019.04.25
SB623, an Investigational Product, Granted Advanced Therapy Medicinal Product Classification by European Medicines Agency
News Release
2024.12.06
The Yield Results of the Second Commercial Production Run for AKUUGO🄬 Suspension for Intracranial Implantation
News Release
2024.11.15
The Results of the First Commercial Production Run to Meet the Approval Conditions for the Shipment of AKUUGO🄬 Suspension for Intracranial Implantation
News Release
2024.09.05
Positive Results of Key Development Product SB623 for Chronic Effects of Traumatic Brain Injury, including Sustained Motor Function Improvement up to 48 weeks, published in Neurology
News Release
2024.07.31
SanBio Obtains Marketing Approval for “AKUUGO🄬 Suspension for Intracranial Implantation” (INN: Vandefitemcel) as a Therapeutic Agent for Improving Chronic Motor Paralysis From Traumatic Brain Injury (TBI)
News Release
2024.07.29
Notice Concerning Notice of Allowance of New Patent for Cell Therapy Using SB623 for Chronic Ischemic Stroke in the US
News Release
2024.07.10
[Results of Basic Research] Publication of an Article on the Neuronal Activity and Network Formation Promotion of the Key Development Product SB623
News Release
2024.06.20
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2024.06.12
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2024.03.26
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2024.03.18
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
Media
2022.04.08
On April 7, NeurologyLive published an interview with Dr. Peter McAllister regarding the final analysis of the Phase 2 STEMTRA trial.
Media
2018.04.20
Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, publishes report in the leading medical journal, Stroke
Info
2024.11.11
MORI, President & CEO, will be a panelist at “Navigating Biopharma Innovation Across the Pacific” hosted by the U.S. Embassy and the Japan Society of Northern California on November 11
Info
2022.12.22
Presentation of Phase 2 STEMTRA Trial Results at The 14th World Congress on Brain Injury
Info
2021.02.22
Head of Regulatory Affairs Japan, Kazumi Sawaguchi, Ph.D., gave a presentation at 5th DIA Cell and Gene Therapy Products Symposium in Japan
Info
2021.01.06
SanBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
Info
2019.12.16
Message from Representative Director and President, Keita Mori, regarding disclosures made on December 13, 2019
Info
2018.12.27
【Announcement】SanBio will present at the 37th Annual J.P. Morgan Healthcare Conference
Info
2018.08.28
【Announcement】SanBio will be featured on NHK WORLD – JAPAN “Medical Frontiers – The Brain Can Be Regenerated” on September 4 (Tue) 4 times a day, Japan timeIt is available for watching on the Internet.
Info
2018.01.10
SanBio presented at the 36th Annual J.P. Morgan Healthcare Conference
Info
2017.11.22
Keita Mori, CEO of SanBio will speak at 2017 World Alliance Forum in San Francisco on November30
Info
2017.11.22
SanBio will present at 2nd DIA Cell Therapy Products Symposium in Japan on December 15"Quality of Regenerative Medical Products -What do we need to start a clinical study in Japan? -" Takehiko Kaneko, Medical Director & Head of Clinical Development Japan, SanBio Co., Ltd.
